echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Take stock: A selection of BMJ studies on September 26, 2020.

    Take stock: A selection of BMJ studies on September 26, 2020.

    • Last Update: 2020-10-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    1. Center Obesity Index and All-Cause Risk Study doi: https://doi.org/10.1136/bmj.m3324 Researchers recently quantified the central obesity index, including waist circumference, hip circumference, thigh circumference, waist-hip ratio, waist-height ratio, waist-to-leg ratio, body obesity index and body type index, through a systematic review and meta-analysis of the study, and the relationship between waist, hip, thigh, waist-hip ratio, waist-height ratio, waist-leg ratio, body obesity index and body type index.
    total of 72 forward-looking cohort studies were included in this meta-analysis, which included 2228,297 participants.
    study found that the risk of death ratio was 1.11 and 0.90 for every 10 cm (3.94 inches) increase in waist circumference and 0.82 for each additional 5 cm of thigh circumference, and 1.20, 1.24 and 1.21 for each additional 0.20, 1.24 and 1.21 per lumbar-to-leg ratio.
    risk ratio of 1.17 for every 10% increase in body obesity index and 1.15 for every 0.005 unit increase in body mass index.
    results were significantly maintained after adjusting for body mass index.
    Researchers found an approximate J-type association between waist circumference and waist-height ratio and all-cause mortality in both men and women, a monotonous positive correlation between waist-to-hip ratio and body mass index and all-cause mortality, and a U-shaped correlation between body obesity index and all-cause mortality.
    : https://doi.org/10.1136/bmj.m3320 Recently researchers examined the clinical manifestations, risk factors, and maternal and perinatal outcomes of pregnant women with suspected or confirmed coronavirus disease (covid-19).
    this systematic review and meta-analysis study included 77 cohort studies in which 11,432 pregnant women were diagnosed with suspected or confirmed covid-19 patients.
    most common clinical manifestations of covid-19 during pregnancy were fever (40%) and cough (39%).
    Compared to non-pregnant women of childbearing age, pregnant women with covid-19 have a lower risk of developing fever symptoms (ratio 0.43) and myalgia (0.48), but are at increased risk of intensive care (1.62) and invasive aeration (1.88).
    73 pregnant women (0.1 per cent) who were diagnosed with covid-19 died.
    age increase (1.78), high body mass index (2.38), chronic hypertension (2.0) and diabetes (2.51) were associated with severe covid-19 pregnancy.
    and past co-diseases are risk factors for intensive care (4.21) and invasive aeration (4.48).
    rate of 6 per cent for Covid-19 mothers.
    women with covid-19 had a higher risk of precocity (3.01) than those who did not have covid-19.
    a quarter of newborns with covid-19 received NICU care (25%), the risk of hospitalization (risk ratio 3.13) increased significantly.
    SGLT2 inhibitors reduce the risk of cardiovascular events in patients with type 2 diabetes Doi: https://doi.org/10.1136/bmj.m3342 Researchers recently examined the effects of sodium glucose cotranserative protein 2 (SGLT2) inhibitors and lipid-peptidease-4 (DPP-4) inhibitors on cardiovascular event risk in patients with type II diabetes.
    compared to DPP-4 inhibitor users, SGLT2 inhibitors used MACE (incidence per 1000 people-years: 11.4 v 16.5; risk ratio 0.76), myocardial infarction (5.1 vs 6.4; 0. 82), reduced risk of cardiovascular death (3.9 vs. 7.7; 0.60), heart failure (3.1 vs. 7.7; 0.43) and all-cause death (8.7 vs. 17.3; 0.60).
    SGLT2 inhibitors had no significant effect on the reduced risk of ischemic stroke in diabetic patients (2.6 v 3.5; 0.85).
    similar effects on MACE for Kaglia Net (0.79), Dagly Net (0.73) and Ipale Net (0.77).
    MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.